Both adjuvant and neo-adjuvant chemotherapy are standard-of-care for fit patients, at least for those with resected or resectable stage 2 or 3 non-small cell lung cancer (NSCLC). There is a strong rationale for perioperative immune checkpoint blockade and targeted therapies, such as ALK- and EGFR-directed tyrosine kinase inhibitors (TKIs).
Should we use neoadjuvant chemotherapy, and not upfront surgery in combination with adjuvant treatment of early stage NSCLC? The answer is still not clear. A previous trial showed no statistically significant differences in disease-free survival (DFS) with the addition of preoperative or adjuvant chemotherapy to surgery . In contrast, a recently published analysis of the National Cancer Database showed that both adjuvant and neoadjuvant chemotherapy result in better survival rates than surgery alone in patients with stage 2 or 3 lung cancer .
“The guidelines of the European Society of Thoracic Surgeons (ESTS...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: ELCC 2019
Current Management of Early Stage NSCLC
Trial Data: Early Stage Lung Cancer
Immunotherapy in Stage 4 Lung Cancer
Trials: Immunotherapy in Stage 4 Lung Cancer
Implementation of Personalised Lung Cancer Care in Clinical Routine
Optimal Management of Brain Metastases in NSCLC
Small Cell Lung Cancer: New Targets
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.